Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALLK NYSE:CVM NASDAQ:INKT NASDAQ:RANI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLKAllakos$0.33$0.33$0.22▼$1.56$29.74M0.151.24 million shsN/ACVMCEL-SCI$3.96-5.0%$3.27$1.98▼$66.60$12.01M0.3205,954 shs417,623 shsINKTMiNK Therapeutics$20.31-12.6%$10.44$4.56▼$76.00$80.95M0.19244,710 shs677,478 shsRANIRani Therapeutics$0.42-0.3%$0.56$0.39▼$3.75$26.27M-0.021.15 million shs1.07 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLKAllakos0.00%0.00%0.00%+0.95%-60.04%CVMCEL-SCI-5.04%+12.18%+72.93%-48.19%-90.70%INKTMiNK Therapeutics-12.65%-68.35%+173.35%+166.19%+93.43%RANIRani Therapeutics-0.31%-35.47%-18.19%-64.48%-88.77%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALLKAllakos3.4024 of 5 stars3.20.00.04.70.02.51.3CVMCEL-SCI0.1215 of 5 stars0.02.00.00.00.60.00.6INKTMiNK Therapeutics2.7936 of 5 stars3.43.00.00.02.81.70.6RANIRani Therapeutics2.3671 of 5 stars3.51.00.00.03.01.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALLKAllakos 2.33Hold$3.00811.58% UpsideCVMCEL-SCI 0.00N/AN/AN/AINKTMiNK Therapeutics 2.75Moderate Buy$37.5084.64% UpsideRANIRani Therapeutics 3.00Buy$7.331,664.52% UpsideCurrent Analyst Ratings BreakdownLatest CVM, RANI, ALLK, and INKT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/18/2025INKTMiNK TherapeuticsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy7/15/2025INKTMiNK TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Neutral$35.007/11/2025INKTMiNK TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform5/16/2025RANIRani TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$14.00 ➝ $4.00(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALLKAllakosN/AN/AN/AN/A$1.93 per shareN/ACVMCEL-SCIN/AN/AN/AN/A$0.15 per shareN/AINKTMiNK TherapeuticsN/AN/AN/AN/A($4.94) per shareN/ARANIRani Therapeutics$1.03M25.50N/AN/A$0.06 per share6.93Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALLKAllakos-$185.70M-$1.32N/AN/AN/AN/A-140.87%-86.22%8/6/2025 (Estimated)CVMCEL-SCI-$26.92M-$12.61N/AN/AN/AN/A-238.05%-104.65%N/AINKTMiNK Therapeutics-$9.51M-$2.520.00N/AN/AN/AN/A-140.72%8/12/2025 (Estimated)RANIRani Therapeutics-$30.02M-$0.990.00N/AN/AN/A-1,258.76%-80.52%8/5/2025 (Estimated)Latest CVM, RANI, ALLK, and INKT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025INKTMiNK Therapeutics-$0.45N/AN/AN/AN/AN/A8/6/2025Q2 2025ALLKAllakos-$0.24N/AN/AN/AN/AN/A8/5/2025Q2 2025RANIRani Therapeutics-$0.19N/AN/AN/AN/AN/A5/15/2025Q1 2025INKTMiNK Therapeutics-$0.61-$0.70-$0.09-$0.70N/AN/A5/13/2025Q1 2025RANIRani Therapeutics-$0.22-$0.22N/A-$0.22N/A$0.20 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALLKAllakosN/AN/AN/AN/AN/ACVMCEL-SCIN/AN/AN/AN/AN/AINKTMiNK TherapeuticsN/AN/AN/AN/AN/ARANIRani TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALLKAllakosN/A6.086.08CVMCEL-SCI0.661.071.09INKTMiNK TherapeuticsN/A0.300.30RANIRani Therapeutics2.750.880.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALLKAllakos84.64%CVMCEL-SCI12.08%INKTMiNK Therapeutics2.87%RANIRani Therapeutics30.19%Insider OwnershipCompanyInsider OwnershipALLKAllakos16.12%CVMCEL-SCI9.93%INKTMiNK Therapeutics22.48%RANIRani Therapeutics45.08%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALLKAllakos19090.38 million74.94 millionOptionableCVMCEL-SCI433.03 million64.67 millionOptionableINKTMiNK Therapeutics303.99 million3.09 millionNo DataRANIRani Therapeutics11063.21 million34.71 millionOptionableCVM, RANI, ALLK, and INKT HeadlinesRecent News About These CompaniesRani Therapeutics Holdings, Inc. (RANI) - Yahoo FinanceJuly 18 at 7:18 PM | finance.yahoo.comRani Therapeutics Shares Drop Sharply Following $3 Million Direct Offering AnnouncementJuly 15, 2025 | msn.comRani Therapeutics Holdings, Inc. Announces Pricing of $3.0 Million Registered Direct OfferingJuly 15, 2025 | globenewswire.comRani Therapeutics (NASDAQ:RANI) Shares Up 8.4% - Here's What HappenedJuly 15, 2025 | americanbankingnews.comRani Therapeutics Shares Surge After ENDO 2025 Presentation AnnouncementJuly 14, 2025 | msn.comRani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating ...July 14, 2025 | bakersfield.comBRani Therapeutics to Present Preclinical Data on RaniPill® Capsule at ENDO 2025 ConferenceJuly 14, 2025 | quiverquant.comQRani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous DeliveryJuly 14, 2025 | globenewswire.comGenelux Appoints Groen as General Counsel From Rani TherapeuticsJuly 8, 2025 | news.bloomberglaw.comNRani Therapeutics announces annual meeting resultsMay 30, 2025 | investing.comRani Therapeutics strikes deal to issue new warrantsMay 21, 2025 | uk.investing.comRANI: 1Q:25 Financial ResultsMay 20, 2025 | finance.yahoo.comRani Therapeutics Announces Research Agreement with ChugaiMay 19, 2025 | globenewswire.comRani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate UpdateMay 13, 2025 | globenewswire.comRani Therapeutics Faces Nasdaq Compliance ChallengeMay 6, 2025 | tipranks.comStifel Nicolaus Remains a Buy on Trevi Therapeutics (TRVI)April 23, 2025 | markets.businessinsider.comRani Therapeutics management to meet virtually with Lake StreetApril 17, 2025 | markets.businessinsider.comRANI: 2024 Financial ResultsApril 3, 2025 | finance.yahoo.comEarnings call transcript: Rani Therapeutics sees stock drop despite narrowing losses in Q4 2024April 2, 2025 | investing.comQ4 2024 Rani Therapeutics Holdings Inc Earnings CallApril 1, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCVM, RANI, ALLK, and INKT Company DescriptionsAllakos NASDAQ:ALLKAllakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.CEL-SCI NYSE:CVM$3.96 -0.21 (-5.04%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$3.97 +0.01 (+0.25%) As of 07/18/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.MiNK Therapeutics NASDAQ:INKT$20.31 -2.94 (-12.65%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$20.82 +0.52 (+2.54%) As of 07/18/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.Rani Therapeutics NASDAQ:RANI$0.42 0.00 (-0.31%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$0.41 0.00 (-0.63%) As of 07/18/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.